On April 18, 2026, President Trump signed Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness,” directing the FDA to prioritize review of psychedelic drugs with Breakthrough Therapy designation and opening a conditional pathway for parallel DEA rescheduling review. Six days later, on April 24, the FDA issued three Commissioner’s National Priority Vouchers (CNPVs) to psychedelic programs. Compass Pathways was named as a recipient and confirmed receipt the same day. On May 13, Compass reported Q1 2026 results that confirmed the practical mechanics of how this acceleration is expected to work — and the limits of it.
This is what changed, with what’s verified and what isn’t.
1. The EO directs CNPVs to psychedelic drugs with Breakthrough Therapy designation — not psilocybin specifically.
The operative language of EO 14401 §2(a) directs FDA to “provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation.” The order is class-agnostic among psychedelics with BTD — psilocybin (Compass and Usona), methylone (Transcend), mebufotenin (BPL-003, GH001), deuterated psilocin (Helus HLP003), and luvesilocin (Reunion RE104) are all potentially in scope. The FDA’s own framing in its April 24 announcement uses the umbrella term “serotonin-2A agonists and related products.”
2. Three CNPVs were issued April 24, 2026.
The FDA announced and Compass confirmed the same day that COMP360 was selected for the CNPV program. The other two recipients were Usona Institute (psilocybin for major depressive disorder) and Transcend Therapeutics (methylone for PTSD). FDA additionally cleared an IND for DemeRx NB’s noribogaine hydrochloride in alcohol use disorder — the first U.S. ibogaine-derivative clinical trial approval. On the same day, FDA granted Compass a rolling NDA submission and review for COMP360.
The CNPV program goal is a “shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards.” Compass CEO Kabir Nath was careful to characterize this as a goal rather than a binding commitment on the May 13 earnings call: “the actual formal clock of about 1 to 2 months, as we understand it, will only start with the submission. And again, to be clear, that’s a goal.”
The reference point: Eli Lilly’s Foundayo (orforglipron) became the first new molecular entity approved under the CNPV program on April 1, 2026 — exactly 50 days after NDA filing, and 294 days before its scheduled PDUFA date.
3. The NDA timeline compressed by about a quarter.
Compass disclosed on the May 13 call that rolling NDA module submission has already begun. The final module is gated on 26-week Part B data from the COMP006 trial, which Compass continues to expect in early Q3 2026. This shifts practical NDA completion from the previously guided Q4 2026 to Q3 2026, with the CNPV review clock starting at submission.
4. DEA rescheduling review may begin earlier — but practical acceleration hasn’t materialized yet.
EO 14401 §5 directs the Attorney General to “initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder.” This contemplates DEA review running parallel to FDA review rather than waiting the statutory 90 days post-approval.
Compass CEO Nath confirmed the company is “accelerating our engagement with the DEA” based on the EO. But Compass’s Chief Commercial Officer Lori Englebert clarified on the same call: “for planning purposes, as of right now, we are not planning for [acceleration] — we will be ready if there’s anything that happens before, but we see no indication that these timelines have shifted forward.” As of May 25, 2026, no DEA Federal Register notice initiating psilocybin rescheduling rulemaking has been published.